Business Watch: Solstice, Element cancel deal; FDA approves daraxonrasib for pancreatic cancer – cen.acs.org

Business Watch: Recent Developments

Solstice and Element have canceled their deal, as reported in cen.acs.org. Additionally, the FDA has approved daraxonrasib for the treatment of pancreatic cancer.